SCHEDULE: Viking Global Trims BridgeBio Pharma Stake to 8.2%

Sentiment:

Beneficial Ownership Update 14 November 2025 4:52 PM

Viking Global Investors and its affiliates have reduced their beneficial ownership in BridgeBio Pharma, Inc. to 8.2% through recent stock sales.

Worse than expectedThe filing indicates a reduction in beneficial ownership by a significant institutional investor, Viking Global Investors, through recent stock sales. This can be perceived negatively by the market as a decrease in confidence or a strategic divestment.

Summary

Viking Global Investors LP and its affiliated entities, including Viking Global Opportunities Illiquid Investments Sub-Master LP, collectively reported beneficial ownership of 15,893,934 shares of BridgeBio Pharma, Inc. Common Stock.
This ownership represents 8.2% of the outstanding Common Stock of BridgeBio Pharma, Inc.
The percentage is calculated based on 192,708,813 shares of Common Stock outstanding as of October 21, 2025, as reported in BridgeBio Pharma's Form 10-Q filed on October 29, 2025.
O. Andreas Halvorsen, David C. Ott, and Rose Sharon Shabet, as Executive Committee Members of Viking Global Partners LLC, share authority over the voting and disposition of these shares.
During the past 60 days, Viking Global's Opportunities Fund sold a total of 374,915 shares of Common Stock in multiple transactions.
These sales occurred on September 29, 2025, and October 15, 2025, at weighted average prices ranging from $51.6696 to $57.1301 per share.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a significant institutional investor reducing its stake in the company, which can be interpreted as a lack of conviction or a strategic shift away from the investment.

Negatives

Viking Global's Opportunities Fund sold 374,915 shares of BridgeBio Pharma Common Stock in September and October 2025, indicating a reduction in their investment stake.

Future Outlook

Industry Context

This filing reflects a change in a significant institutional investor's position in BridgeBio Pharma, Inc., a biotechnology company. Such adjustments by major funds like Viking Global are closely watched by the market as they can signal shifts in investor confidence or portfolio rebalancing within the competitive biotech sector.

Stakeholder Impact

Shareholders may view the reduction in stake by a major institutional investor as a negative signal, potentially impacting investor confidence and the company's stock price.
The company's management might face questions regarding the reasons behind the institutional investor's decision to reduce its holdings.

Key Dates

Date	Description
2019-07-08	Initial Schedule 13D filed with the Commission.
2023-07-19	Amendment No. 1 to Schedule 13D filed.
2023-11-22	Amendment No. 2 to Schedule 13D filed.
2024-08-20	Amendment No. 3 to Schedule 13D filed.
2024-11-06	Amendment No. 4 to Schedule 13D filed.
2025-01-31	Amendment No. 5 to Schedule 13D filed.
2025-03-12	Amendment No. 6 to Schedule 13D filed.
2025-07-01	Amendment No. 7 to Schedule 13D filed.
2025-08-14	Amendment No. 8 to Schedule 13D filed.
2025-09-29	Opportunities Fund sold 291,000 shares of Common Stock at a weighted average price of $51.6696.
2025-10-15	Opportunities Fund sold 55,018 shares of Common Stock at a weighted average price of $56.7955.
2025-10-15	Opportunities Fund sold 28,897 shares of Common Stock at a weighted average price of $57.1301.
2025-10-21	Date as of which 192,708,813 shares of Common Stock were outstanding, used for percentage calculation.
2025-10-29	BridgeBio Pharma, Inc. filed its quarterly report on Form 10-Q with the SEC.
2025-11-14	Date of event requiring filing of this Amendment No. 9 to Schedule 13D.

Recommendation

hold

While a significant institutional investor has reduced its stake, this filing primarily provides an ownership update rather than new operational or financial performance data. The reduction in stake by Viking Global could be a signal, but without further context on the company's fundamentals or the investor's specific rationale, a 'hold' recommendation is prudent. Investors should monitor future filings and company performance for a more comprehensive assessment.

Keywords

BridgeBio Pharma, Viking Global Investors, Schedule 13D/A, Beneficial Ownership, Stock Sales, Institutional Investor, Biotechnology, Pharmaceuticals

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.